14
ELV
ELEVANCE HEALTH INC FORMERLY · Financials
Consensus score 14/100 · #32 this quarter · tier-weighted across tracked managers
→NeutralPrice action since filingas of 2026-07-10
vs 50-day avg
+5.2%
21-day momentum
-1.9%
recent volume
0.90×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S2· AdvancingStage Analysis · Weinstein
vs 30-wk avg
+18.2%
30-wk MA slope
+3.2%
rel. strength
+14.4
52-wk range
93%
Advancing — above a rising 30-week trend with positive relative strength. Weinstein’s buy zone. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
8
tracked managers
New this Q
1
opened a position
Avg weight
3.4%
of their portfolios
Combined value
$1.71B
held, at quarter-end
Who’s holding it Q1 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Brave Warrior Concentrated | 8.1% | $329M | TRIM |
| Baupost Group Deep value | 7.3% | $373M | HOLD |
| Ruane Cunniff / Sequoia Quality compounder | 6.7% | $406M | TRIM |
| Hosking Partners Concentrated | 1.6% | $45M | ADD |
| Eagle Capital Quality value | 1.5% | $453M | ADD |
| Yacktman Asset Management Quality value | 1.3% | $98M | ADD |
| Hound Partners Concentrated | 0.1% | $1M | NEW |
| Tweedy Browne Graham/global value | 0.1% | $1M | ADD |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.